Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Steven Mog"'
Autor:
Kaytee L. Pokrzywinski, Thomas G. Biel, Elliot T. Rosen, Julia L. Bonanno, Baikuntha Aryal, Francesca Mascia, Delaram Moshkelani, Steven Mog, V. Ashutosh Rao
Publikováno v:
Biology of Sex Differences, Vol 9, Iss 1, Pp 1-17 (2018)
Abstract Background Doxorubicin (DOX), an anthracycline therapeutic, is widely used to treat a variety of cancer types and known to induce cardiomyopathy in a time and dose-dependent manner. Postmenopausal and hypertensive females are two high-risk g
Externí odkaz:
https://doaj.org/article/e079b32ae31b427b80589dfdcb260e8d
Autor:
Jennifer S Dickey, Yanira Gonzalez, Baikuntha Aryal, Steven Mog, Asako J Nakamura, Christophe E Redon, Ulrich Baxa, Elliot Rosen, Gang Cheng, Jacek Zielonka, Palak Parekh, Karen P Mason, Joy Joseph, Balaraman Kalyanaraman, William Bonner, Eugene Herman, Emily Shacter, V Ashutosh Rao
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70575 (2013)
Several front-line chemotherapeutics cause mitochondria-derived, oxidative stress-mediated cardiotoxicity. Iron chelators and other antioxidants have not completely succeeded in mitigating this effect. One hindrance to the development of cardioprotec
Externí odkaz:
https://doaj.org/article/7060670eeb5e44eba014664c9b3a8f2b
Autor:
Toshiki Tomori, Anne McKeague, Walter Carr, Mariam Grace Delima, Richard M. McCarron, Francoise Arnaud, Krishnanurthy Govindaraj, Charles W. Beadling, Clifford Lutz, Steven Mog, McNamee Ga, Dione Parreño-Sadalan, David Burris, Trueman W. Sharp, Kohsuke Teranishi
Publikováno v:
The Journal of trauma. 67(4)
Major improvements have been made in the development of novel dressings with hemostatic properties to control heavy bleeding in noncompressible areas. To test the relative efficacy of different formulations in bleeding control, recently manufactured
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f08063ccc4a47c29c7b3e1f1a1893f47
https://pubmed.ncbi.nlm.nih.gov/19820595
https://pubmed.ncbi.nlm.nih.gov/19820595
Autor:
Steven Mog, Eugene H. Herman, Ashutosh Rao, Baikuntha P. Aryal, Yanira Gonzalez-Berrios, Karen P. Mason, William M. Bonner, Christophe E. Redon, Palak R. Parekh, Ulrich Baxa, Jennifer S. Dickey, Asako J. Nakamura, Elliot T. Rosen
Publikováno v:
Cancer Research. 73:1386-1386
Doxorubicin is a chemotherapeutic drug that causes oxidative stress-mediated cardiotoxicity. To prevent oxidative stress and help to mitigate the cardiotoxic effects of doxorubicin, the iron chelator dexrazoxane is clinically used. However, iron chel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b813ac3d50a0a1eefb7d1bdecbf34628
https://doi.org/10.1158/1538-7445.am2013-1386
https://doi.org/10.1158/1538-7445.am2013-1386